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     Despite great success of GWAS in identification of common genetic variants associated 
with complex diseases, the current GWAS have focused on single SNP analysis.  However, 
single SNP analysis often identifies a number of the most significant SNPs that account for 
only a small proportion of the genetic variants and offers limited understanding of complex 
diseases. To overcome these limitations, we propose gene and pathway-based association 
analysis as a new paradigm for GWAS.   As a proof of concept, we performed a 
comprehensive gene and pathway-based association analysis for thirteen published GWAS.  
Our results showed that the proposed new paradigm for GWAS not only identified the 
genes that include significant SNPs found by single SNP analysis, but also detected new 
genes in which each single SNP conferred small disease risk, but their joint actions were 
implicated in the development of diseases.   The results also demonstrated that the new 
paradigm for GWAS was able to identify biologically meaningful pathways associated with 
the diseases which were confirmed by gene-set rich analysis using gene expression data. 
      Genome-wide association studies (GWAS) armed with efficient genotyping technologies are 
emerging as a major tool to identify disease susceptibility loci and are successful to detect 
association of a number of SNPs with complex diseases1-12.  However, to only test for 
association of single SNP is insufficient to dissect complex genetic structure of complex diseases.  
To extract biological insight from GWAS and to understand the principles underlying complex 
phenomena that take place on various biological pathways remain a major challenge. In a typical 
GWAS, hundreds of thousands of SNPs are genotyped for thousands of individuals. By 
comparisons of differences in the DNA variations between the normal and affected individuals, 
the SNPs can be ordered according to their degrees of association.  The common approach is to 
select dozens of the most significant SNPs in the list for further investigations. This approach 
which takes only SNPs as basic units of association analysis has a few serious limitations. First, 
the single SNP showing significant association with complex diseases typically has only mild 
effects13.  The common disease often arises from joint action of multiple loci within a gene or 
joint action of multiple genes within a pathway. Although each single SNP may confer small 
disease risk, their joint actions will play a significant role in the development of disease. If we 
only consider the most significant SNPs, the genetic variants that jointly have significant risk 
effects, but individually make only a small contribution, will be missed.  Second, locus 
heterogeneity, in which alleles at different loci cause disease in different populations, will 
increase difficulty in replication of association of single marker14.  The list of significant SNPs 
from several studies may rarely overlap.  A gene, particularly, a pathway, consists of a group of 
interacting components acting in concert to perform specific biological tasks. Replication of 
association finding at the gene level or pathway level is much easier than replication at the SNP 
level.  Third, attempting to understand and interpret a number of significant SNPs without any 
unifying biological theme can be challenging and demanding.  SNPs and genes carry out their 
functions through intricate pathways of reactions and interaction.  The function of many SNPs 
may not be well characterized, but function of genes and particularly pathways, on the contrary, 
are much better investigated. Therefore, the gene and pathway-based association analysis should 
allow to gain insight into the functional basis of the association and facilitate to unravel the 
mechanism of complex diseases.  
     To meet conceptual and technical challenge raised by GWAS and take full advantage of the 
huge opportunities provided by GWAS, a complementary approach to genome-wide search 
association of single SNP with the disease is gene and pathway association analysis.  The gene 
and pathway-based association analysis is to take a gene or pathway as a basic unit of analysis. 
The gene and pathway-based GWAS aim to simultaneously study association of a group of 
genetic variants in the same biological pathway14-16, which help us to holistically unravel 
complex genetic structure of common disease to gain insight into the biological processes and 
disease mechanism17.   
    The gene and pathway-based GWAS can be performed by extension of gene set enrichment 
analysis for gene expression data, which intend to identify subtle, but coordinated expression 
variations of gene groups18, to genome-wide association studies. This will open a new avenue for 
association analysis. However, simple application of gene set analysis methods for gene 
expression data to GWAS may not work very well. The key difference between the gene 
expression data and SNP data is that in expression data each gene is represented by one value of 
expression level of the gene, but in GWAS each gene is represented by a variable number of 
SNPs. The challenge facing us is how to represent a gene. Wang et al.19 proposed to choose the 
most significant SNP from each gene as a representative. As Casci20 pointed out “Given that 
each gene is associated with more than one SNP, how do you choose the most representative one? 
And how do you correct for the fact that longer genes have more SNPs than shorter ones?”. In 
other words, applying gene set enrichment analysis methods to GWAS requires developing gene-
based association analysis that takes gene as a basic unit of association analysis. One promising 
approach is to combine P-values for correlated SNPs into an overall significance level to 
represent a gene and to combine P-values for the genes into an overall significance level to 
investigate association of a pathway with the disease21.   
RESULTS     
    To investigate what should be the basic units for genome-wide association studies and  to 
illustrate how to perform  the gene and pathway-based genome-wide association analysis, we 
examine the thirteen  published GWAS (Supplementary Table 1 online), where WTCCC 
represents Wellcome Trust Case Control Consortium,  NARAC,  the North American 
Rheumatoid Arthritis Consortium, EIRA, the Swedish Epidemiological Investigation of 
Rheumatoid Arthritis,  DGI, Diabetes Genetics Initiative, AREDS, The Age-Related Eye Disease 
Study, CORIELL,  Coriell Institute for Medical Research, and ten diseases:  bipolar disorder 
(BD), coronary artery disease (CAD), Crohn's disease (CD), hypertension (HT), rheumatoid 
arthritis (RA), type 1 diabetes (T1D), type 2 diabetes (T2D),  Parkinson's Disease (PD), Age-
Related Eye Disease  (AREDS) and  Usuals.  Since only P-values for testing association of 
single SNP (but not individual genotypes) were publically accessible, we used the statistical 
methods for combining independent P-values to perform gene and pathway-based GWAS (see 
Methods). The methods for combining dependent P-values require individual genotype 
information and cannot be applied here.  The number of typed cases and controls, the number of  
typed SNPs and genes, and P-values for ensuring genome-wide significance using Bonferroni 
correction for each study are listed in Supplementary Table 1. 
     In principle, there are three basic units for genome-wide association studies: SNP, gene and 
pathway. The current GWAS are limited to taking a SNP as the basic unit for association testing. 
Now we present the results where the basic unit of association tests is a gene or a pathway. The 
procedure for gene and pathway-based GWAS consist of two steps. The first step is to combine a 
set of P-values for SNPs in a gene, which is obtained from GWAS of single SNP, into an overall 
significance level of the gene. The second step is to combine a set of P-values for genes in a 
pathway into an overall P-value for the pathway.  To combine P-values, one typically assumes 
that the P-values are independent and uniformly distributed under their null hypothesis. In this 
report, four combination tests: Fisher combination test, Sidak combination test, Simes’ 
combination test and a test based on false discovery rate were used (See methods). Since the 
SNPs within a gene may be in linkage disequilibrium, P-values of SNPs from the same gene are 
often not independent and hence independent assumption of combining P-values is violated.  We 
used methods for combining independent P-values for the following reasons. First, the methods 
for combining dependent P-values require data with individual genotypes. However, in many 
cases, individual genotypes cannot be publically accessed. Second, errors that arise from 
violation of independent assumption are not very high (We will present the results of comparison 
of methods combining independent P-values and combining dependent P-values elsewhere).  
Third, Q-Q plots for the four combining tests (Supplementary Figure 1) showed that the 
observed distribution of P-values of the combining tests (except for Fisher combination test) 
matches expectation for the majority of the data, but starts to depart from the null at 3.15 610−×  
(gene) and 410−  (pathway).  
     We obtained the combined P-values for each gene. Supplementary Table 2a and 2b summarized 
total number of significant genes, significant SNPs and significant SNPs which belong to 
insignificant genes.  Figures 1A and 1B plotted –log10 of the P-value of Fisher and Simes 
combination tests for association of the gene with disease, respectively.  The number of replicated 
SNPs and genes in the different studies or the number of significant SNPs and genes shared by 
several diseases was listed in Table 1. In Supplementary Tables S3-S15 we listed all significant 
genes with P-values  61015.3 −×≤  which were calculated by Fisher combination test or by the test 
based on the false discovery rate (FDR) for thirteen studies. In these tables we also included the 
number of typed SNPs within each significant gene and P-value of the most significant SNP in the 
gene.  Supplementary Tables S16-S18 listed the significant SNPs and genes for PA, RA and T2D 
diseases shared by two independent studies. Three remarkable features emerge from these tables. 
First, similar to SNPs, the gene can also be considered as a basic unit for association testing.  
These tables showed that except for the diseases RA and T1D, the number of significant SNPs in 
each study is very small, but the number of significant genes is quite large. From these tables we 
can find that the large proportion of significant genes even contains no single significant SNP. For 
example, in T2D study (WTCCC), the P-values of the best SNPs in the genes PPARG,  JAZF1, 
TSPAN8 and THADA were  0.001205,  0.001681, 0.0000156, 0.01080, respectively,   but the 
overall P-values of these genes were 2.87 ,10 5−× 71058.8 −× , ,1017.3 13−×  51080.1 −× ,respectively.  
Although   initial single SNP analysis did not find any significant SNPs in these genes, the recent 
meta-analysis24 showed that   the P-values of the best SNPs in these genes were 2.00 710−× , 
5.00 1410−× , 91010.1 −×  and 91010.1 −× , respectively. This demonstrated that the results of the 
gene-based association analysis were consistent with the results of meta-analysis. If we only 
conduct the single SNP association analysis, these significant genes might be missed due to low 
power of small sample sizes in the initial GWAS.  Second, replication of association finding that 
results from gene-based approach in additional independent samples were much easier than that 
from single  SNP association analysis.  We examined association studies of three diseases: T2D, 
PA and RA, each with two independent studies.   For T2D, no SNPs were replicated in two 
independent studies (WTCCC and DGI) after correction for multiple test by Bonferroni method. 
However, seven genes including genes TCF7L2 (transcription factor 7-like 2) and CDKAL1 
(CDK5 regulatory subunit associated protein 1-like 1) were replicated (Supplementary Table 
S17). The gene TCF7L2 which has a marked effect on type 2 diabetes was widely replicated 
association in several studies 2,23. In single SNP association analysis, although strong association 
of CDKAL1 was reported from WTCCC (P=1.02 610−× ) and from WTCCC/UKT2D2,3 (P= 810− ), 
the original scan and follow up replication samples from DGI only support nominal association 
(P=0.0024). In gene-based analysis, its strong association was observed from WTCCC (P < 2010− ) 
and DGI (P= 61084.1 −× ) (Supplementary Table S17). Although the function of CDKAL1 is 
unknown, nominal association of the risk allele with reduced insulin secretion in controls was 
reported in DGI study (P=0.01)23.  To explain why replication of the significant gene in 
independent samples is much easier than replication of the significant SNP we presented Table 2 
in which all SNPs with P-values < 0.05 in the genes were listed. Table 2 demonstrated that 
although few single SNP in the genes CDKAL1, TTLL5 and BTBD16 showed significant 
association in WTCCC study or DGI study, the joint effects of multiple SNPs with very mild 
effects made three genes to be strongly associated with the diseases in both studies. Third, the 
gene-based association analysis will more effectively identify the common genes that are shared 
within a disease group than the single SNP association analysis. Although there is considerable 
heterogeneity among complex diseases, many diseases share common phenotypes, forming a 
group of diseases.  In the studies which we examined here, CD+RA+T1D are autoimmune 
diseases, and CAD+HT+T2D have metabolic and cardiovascular phenotypes in common. GWAS 
offer us opportunity to reveal the genetic variants that confer risk to more than one disease.  
Supplementary Table 19 summarized the shared genes within the disease group based on the best 
SNP within the gene. In other words, a gene is shared within a disease group if at least one 
significant SNPs in the gene are in common within the disease group.  As Supplementary Table 
19 shown, based on the most significant SNPs in the gene shared within a disease group, we can 
only find the shared genes in the RA+T1D disease group. However, if we perform gene-based 
association analysis, as Supplementary Table 20 shown, we can find a number of shared genes 
within CD+RA+T1D, CAD+HT+T2D   and RA + T1D disease groups.  This demonstrated that to 
detect genetic variants at the SNP level may run a high risk of missing shared genes within the 
disease group. Although we cannot confirm all these findings at this stage, some genes in 
Supplementary Table 20 were reported to be associated with either autoimmune diseases or 
metabolic diseases. For example, it was widely reported that HLA-DQA2 and HLA-DQB2 were 
involved in autoimmune diseases and GBE1 was associated with metabolic syndrome.     
         Numerous genome-wide gene expression analyses have shown that single-gene analysis 
finds little similarity between two independent studies, but pathway-based analysis may find a 
number of pathways in common24.  These results imply that pathway-based analysis coupled with 
gene-based analysis may also provide an analytic tool for interpreting the results of GWAS to 
unravel complex genetic structure of the diseases19. Pathway analysis is to identify pathways that 
are significantly associated with the disease. In other words, we attempt to test whether the 
pathway is overrepresented by the genes which are significantly associated with the disease. The 
hypergeometric test (Fisher’s exact test), several combining P-value methods (Fisher combination 
test, Sidak combination test, Simes’ combination test and a test based on false discovery rate)  
were used to test significant association of pathway with the disease (See methods).  We 
assembled 465 pathways from KEGG25 and Biocarta (http://www.biocarta.com).   Table 3 
summarized the number of significant pathways  and Table 4 summarized the number of replicated 
pathways associate with the diseases RA, T2D and PA in two independent studies or the number 
of  pathways shared within the diseases  CAD+HT+T2D, RA+T1D, and CD+RA+T1D in the 
WTCCC studies.  These significant pathways were identified by   overrepresentation test and 
Simes/FDR method. Supplementary tables 21-33 summarized all significant pathways with P-
values  01.0≤  which were calculated by Fisher exact test or by Simes/FDR method for thirteen 
studies.  Supplementary tables 34-36 listed all significant pathways associated with the diseases 
RA, T2D and PA which were replicated in two independent studies and Supplementary tables 
37-39 listed the significant pathways shared by the disease groups: CAD+HT+T2D, RA+T1D and 
CD+RA+T1D. These tables demonstrated several remarkable features that should be used to 
extract biological insight from GWAS. First, the paradigm of genetics of complex diseases is that 
the combined actions of DNA variants within pathways play an essential role in predisposing to 
diseases while the genetic effects of individual gene may be small. Therefore, functional pathway 
analysis is a key to unraveling mechanism of complex diseases and opens a way toward a pathway 
definition of complex diseases. Biological pathways are sets of genes that work in concert to 
perform particular cellular functions or biological processes.  As Table 3 shown, much larger 
proportion of pathways was significantly associated with the disease than that of genes, let alone 
SNPs. This implied that pathways play essential roles in causing disease. We note that many 
identified pathways showing significant association form the core of pathway definition of 
complex diseases. For example, MAPK pathway, JNK pathway, the ubiquitin-proteasome pathway, 
O-Glycan biosynthesis and Axon guidance which showed significant association with the PD in 
two studies (CORIELL and NCBI) have been reported as a set of major pathways implicated in 
PD26,27. T2D is caused by excessive production of glucose, decreased insulin secretion, and insulin 
resistance, which lead to oxidative address and activate stress-sensitive signaling pathways28. 
Pathway-based association analysis identified NF-kB, p38 MAPK,  Angiotensin II mediated 
activation of JNK Pathway, Activation of PKC through G protein coupled receptor pathway, Wnt 
signaling pathway, Adherens junction, Melanogenesis, ECM-receptor interaction and Vitamin C in 
the Brain pathway, which form the major pathways defining T2D (Supplementary Table 40). 
Second, results of pathway-based GWAS can be verified by functional pathway enrichment 
analysis of gene expressions. For example, RA is an autoimmune disease. Its major feature is 
chronic inflammation of joints. Our pathway-based association analysis identified Cytokine-
cytokine receptor interaction, IFN α  signaling,  , Jak-STAT signaling, Complement and 
coagulation cascades,  and Fatty acid biosynthesis pathways that were confirmed by pathway 
enrichment analysis of gene expression profiling of peripheral blood cells of RA29. Third, 
replication of the results of pathways in independent samples is much easier than replication of 
genes or SNPs.  One strategy to meet the major challenge of separating the large number of false-
positive associations from the true positive associations in GWAS is to replicate the results in 
independent studies. Replications are a major strategy for confirmation of association results. 
Replications can be performed at the level of the SNP, the gene and pathway. As Table 1 shown, 
no significant SNPs (using Bonferroni method for correction of multiple tests) in T2D GWAS can 
be replicated and only seven significant genes can be replicated in the WTCCC and DGI studies.  
However, 10 (Simes/FDR) or 5 (Fisher exact test) pathways can be replicated (Table 4).   Risk 
genes for different individuals may be different, but may be in the same pathway. Identification of 
pathways associated with disease allows us to much easily discover pathogenesis of disease.   
Figures 2A and 2B plot the GnRH signaling pathway that was associated with  RA in the WTCCC  
studies with P-value  141048.1 −×≤ (Fisher combination test), P-value 025.0≤ (Fisher Exact Test) 
and P-value 017.0≤ (Simes/FDR) and NARAC & EIRA studies with P-value 171000.1 −×≤  
(Fisher combination test), P-value 0055.0≤ (Fisher Exact Test) and P-value 
61039.1 −×≤ (Simes/FDR) . Although GnRH pathway was significantly associated with RA in 
both studies, the genes that turned significant association in two studies were different.  Two paths: 
Gs Æ AC Æ PKA Æ Gonadotropins gene expression & secretion and MAPK pathway (GRB2 Æ 
Sos –>  Ras Æ Raf1 Æ MEK1/2 Æ ERK1/2 Æ Gonadotropins gene expression & secretion) are 
involved in  GnRH pathway. In WTCCC studies, several genes GNAS (Gs, P-value < 0.0097), 
ADCY2 (AC, P-value < 0.000191) and PRKACB (PKA, P-value < 4.48 610−× ) in the first path 
showed strong association or mild association, but did not show any association in NARAC & 
EIRA studies.  The genes in the second path (MAPK pathway): GRB2 (P-value <1.27 510−× ), 
KRAS (Ras, P-value < 7.77 610−× ) and MAP2K1 (ERK, P-value < 0.005) were associated with 
RA in NARAC & EIRA studies, but not in WTCCC studies. It has been a long-time to discuss that 
endocrine system may play critical role in the pathogenesis of RA. Gonadotropins are hormones 
secreted by gonadotrope cells of the pituitary gland. The two major gonadotropins are luteinizing 
hormone (LH) and follicle stimulating hormone (FSH). LH stimulates secretion of sex steroids 
from the gonads. FSH stimulates the maturation of ovarian follicles in women and support sperm 
cell maturation in men. Gonadotropins have marked immunomodulatory properties and may play 
important roles in the pathogenesis of various immune-regulatory diseases. Sex hormone levels 
including estrogen and/or progesterone in women and testosterone in men are reported relatively 
low in most RA patients. Clinical onset of RA also shows hormone- related pattern30. Typically, 
the peak incidence of RA in women is during menopause, while the disease in men occurs after 
age 45. These observations are consistent with gonadotropins associated disease mechanisms. It is 
interesting to note that the P-values of the best SNP in gene PRKACB, GRB2 and KRAS were 
0.013, 0.006 and 0.0012, respectively.  This example showed that each SNP may confer small 
contribution, but their joint actions may affect function of the pathway which in turn will cause 
disease. These results strongly challenge the current strategy for genome-wide association studies 
which was limited to taking only single SNP as basic unit for association testing.   
DISCUSSION 
In the past two years we have witnessed the success of the first wave of large-scale GWAS.  
Despite rapid progress in GWAS, the most widely used approach to GWAS is individual SNP 
association analysis. In other words, it evaluates the significance of individual SNPs.  However,  
GWAS at only SNP level have two serious limitations. First, the final result of individual SNP 
association analysis is determined by the selected significance level. The different choice of the 
significance level will severely affect the list of significant SNPs. Many SNPs with moderate 
genetic effects are discarded by the strict threshold.  Therefore, the list of most significant SNPs   
account for only a small proportion of the genetic variants of complex traits and are  unable to 
reveal holistic genetic structure.  Second, Single individual SNP association analysis separates 
association finding from biological interpretation.  It offers limited understanding of complex 
diseases as an integrated whole.  What should be future developments for GWAS?  To address 
this issue, we proposed to take a system biology approach, which considers not only SNP, but 
also gene and pathway as a basic unit of GWAS, to deciphering complex path from genotype to 
phenotype.  
The proposed paradigm for GWAS consists of three components: SNP-based, gene-based and 
pathway-based association analyses.  Gene and pathway-based association analysis assesses the 
significance of the genes and the predefined pathways, and intends to identify biological 
pathways with subtle but coordinated genetic variants that confer risk contributions. We 
performed a comprehensive gene and pathway-based GWAS for eleven diseases, assuming that 
the results of single SNP association analysis are available.  Our results showed that the proposed 
new paradigm for GWAS not only identified the genes that include significant SNPs found by 
single SNP analysis, but also detected new genes in which each single SNP conferred small 
disease risk, but their joint actions were implicated in the development of diseases.  We verified 
the new genes that were identified by the new paradigm for GWAS from two aspects. First, these 
new findings were replicated in two independent samples. Second, the SNPs that are located in 
the new identified genes were not significant in any of their original studies, but showed strong 
association in the recently published meta analysis of genome-wide association data and large-
scale replication.  Our results also strongly demonstrated that replication of association finding at 
the gene or pathway level is much easier than replication at the individual SNP level. One of the 
major advantages offered by the new paradigm for GWAS is that pathway-based analysis can 
add structure to genomic data and allows us to gain insight into the deep understanding of 
cellular processes as intricate networks of functionally related genes.  We further demonstrated 
that the new paradigm can also offer the opportunities for finding the pathways that are common 
within disease groups.  We used RA as an example to show that the identified pathways by the 
new paradigm for GWAS can be confirmed by gene-set rich analysis using gene expression data. 
This implies that the new paradigm for GWAS will open a novel avenue to integrate GWAS with 
other functional analyses and hence will facilitate to uncover the mechanism of complex diseases.  
Since the current GWAS only report the P-value for single SNP, and the individual genotype 
data is not publically available, our methods for gene and pathway-based GWAS are designed 
for the P-value data.  The major tool for gene and pathway-based analyses is to combine 
independent P-values of single SNP in the gene into an overall P-value for the gene and 
independent P-values of single gene in the pathway into an overall P-value for the pathway.  
Since the SNPs in a gene are often dependent, we need methods for combining dependent P-
values, which in turn require individual genotype information. The limitation of the proposed 
gene and pathway-based association analysis which is based on combining independent P-values 
is applied to dependent  data. The gene and pathway-based analysis that uses the methods to 
combine dependent P-values will be needed.  The results of the gene and pathway-based GWAS 
that take correlations among the SNP and genes into account will be performed in the near future.   
     In the coming years we will see the rapid progress in GWAS. Many challenging tasks for 
GWAS  are that we not only need  to develop powerful statistical methods for detection of as 
many association of genetic variants as possible, but also need to study functional basis of 
association and to gain insight into deeper and deeper understanding of mechanism of complex 
diseases. To unravel the true nature of complex diseases can only be gained by integration of 
multiple approaches and multiple types of data. As a proof of concept, we showed that the gene 
and pathway-based GWAS can provide a general framework for combining genetic studies with 
other functional analyses. We expect that gene and pathway-based analysis will become second 
wave of large-scale GWAS.  
METHODS 
Gene-based association analysis. A gene consists of a number of SNPs.  Typical results for 
association studies are the P-values for testing association of the single SNP with the disease. 
Statistics for testing association of a gene with the disease were conducted on the basis of the 
combination of P values of the SNPs in the gene14. We assume that the P-values iP  are 
independent and uniformly distributed under their null hypotheses although independent 
assumption may be violated due to linkage disequilibrium (LD) among SNPs in the gene.  
Several methods were used to combine independent P values. A general framework for 
combining independent P-values is as follows. Let iP  be the p-value for corresponding statistic 
iT  with G distribution to test the i-th marker iM . Then, iP  is a random variable with a uniform 
distribution on [0,1]. Under the null hypothesis (G distribution), the common form for combining 
P-values is to make transformation. Let H be a continuous monotonic function. A transformation 
of P-value is defined as  
)1(1 ii PHZ −=
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Fisher Combination Test.   
The full combination methods are to combine P-values of all SNPs within the gene. The statistic 
for combining K independent P-values or combining information from K SNPs, is usually given 
by 
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Sidak Combination Test (The Best SNP) 
 If we consider only the best SNP in the gene, then the statistic is defined as  
)1(PZB = . 
The distribution of BZ  is given by  
K
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which is also referred to as Sidak’s correction. 
Simes’ Combination Test 
Let P-values be ordered as )()2()1( ... kPPP ≤≤ . The P-value is calculated as 
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The FDR methods 
Let π  be the proportion of tests with a true null hypothesis and )(αF  be the expected proportion 
of tests yielding a P-value less than or equal toα , )(αV  be the expected proportion of tests 
resulting in a false positive with significant levelα . 
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)()2()1( ... mqqq ≤≤≤  is the ordered false discovery rates. 
We also take 
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as the false discovery rate for the gene or pathway19.  
Pathway-based association analysis. 
Consider m genes in a pathway. Assume that P-value for each gene is calculated by one of the 
methods to combine independent P-values in the previous section.  The methods for testing 
association of pathway with the disease are given below. 
Hypergeometric Test (Fisher Exact Test).  Fisher exact test is to search for an 
overrepresentation of significantly associated genes among the genes in the pathway.  We 
assume that the total number of genes that are of interests is N. Let S be the number of genes that 
are significantly associated with the disease (P-value 05.0≤ and is calculated by Fisher 
combination test) and m be the number of genes in the pathway. Also let k be the number of 
genes significantly associated genes in the pathway.  The P-value of observing k significant 
genes in the pathway is calculated by  
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Sidak method.  Both P-values for testing association of gene and pathway are calculated by 
Sidak method that is described in previous section. 
Simes’ method. Both P-values for testing association of gene and pathway are calculated by 
Simes’ method that is described in previous section. 
Simes/FDR method.  The P-value for testing association of the gene is calculated by Simes’ 
method and the P-value for testing association of the pathway is calculated by FDR method.  
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Legend  
Figure 1A.  Gene-wide scan for eleven diseases. For each of eleven diseases, -log10 of the P 
value of Fisher combination test for association of the genes are plotted against position on 
genome. P values < 5101 −× are represented by circles. All diseases that were not indicated by 
studies in the Figure were performed in the WTCCC studies.  
Figure 1B.  Gene-wide scan for eleven diseases. For each of eleven diseases, -log10 of the P 
value of Simes combination test for association of the genes are plotted against position on 
genome. P values < 5101 −× are represented by circles. All diseases that were not indicated by 
studies in the Figure were performed in the WTCCC studies.  
Figure 2A. P values of genes in GnRH pathway for RA in WTCCC studies. Blocks containing 
significant genes are in red color, Blocks containing mild significant genes are in light red color 
and blocks containing no significant genes are in green color. 
Figure 2B. P values of genes in GnRH pathway for RA in NARAC & EIRA studies. Blocks 
containing significant genes are in red color, Blocks containing mild significant genes are in light 
red color and blocks containing no significant genes are in green color. 
Supplementary Figure 1. Q-Q plots for Fisher combination test, Simes combination test,  
Sidak combination test and test base on false discovery rate applied to T2D (WTCCC). The P-
values for the corresponding combination tests are plotted (as -log10 values) as a function of p 
values from the expected (uniform) null distribution either before or after removing significant 
P-values  (<3.15 610−×  for genes or < 410− for pathways). 
Supplementary Figure 1A.  Q-Q plots for the Fisher combination tests of genes before 
removing significant P-values. 
Supplementary Figure 1B.  Q-Q plots for the  Fisher combination tests of genes after removing 
significant P-values. 
Supplementary Figure 1C.  Q-Q plots for the Simes combination tests of pathways before 
removing significant P-values. 
Supplementary Figure 1D.  Q-Q plots for the Simes combination tests of pathways after 
removing significant P-values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1a.  Number of replicated or shared SNPs and genes (Fisher method) 
Study 1 Study 2 Number of  
replicated  or 
shared SNPs 
Number of  
replicated or 
shared SNPs 
which are not 
located in 
significant 
genes 
Number of  
replicated or 
shared genes 
RA (WTCCC) RA(NARAC & 
EIRA) 
28 0 42 
T2D (WTCCC) T2D (DGI) 0 0 7 
PD(CORIELL) PD(NCBI) 4 4 82 
WTCCC 
CAD+HT+T2D 0 0 6 
RA+T1D 29 0 57 
CD+RA+T1D 0 0 5 
 
Table 1b.  Number of replicated or shared SNPs and genes (FDR method) 
Study 1 Study 2 Number of  
replicated  or 
shared SNPs 
Number of  
replicated or 
shared SNPs 
which are not 
located in 
significant genes 
Number of  
replicated or 
shared genes 
RA (WTCCC) RA(NARAC & 
EIRA) 
28 0 36 
T2D (WTCCC) T2D (DGI) 0 0 0 
PA(CORIELL) PA(NCBI) 4 2 4 
WTCCC 
CAD+HT+T2D 0 0 0 
RA+T1D 29 0 35 
CD+RA+T1D 0 0 0 
 
 
 
 
 
 
Table 2.  Overall P-values of the genes CDKAL1, TTLL5 and BTBD16 and their SNPs with P-
values less  than 0.05 in WTCCC and DGI studies. 
  WTCCC   DGI 
Gene P-value Gene 
 P-
value Gene 
P-
value Gene 
 P-
value 
CDKAL1 
<1.0E-
20 TTLL5 3.0E-15 CDKAL1 2.0E-6 BTBD16 1.0E-6 
N0 of SNPs 126 N0 of SNPs 25 N0 of SNPs 114 N0 of SNPs 30 
SNP P-value SNP 
P-
value SNP 
P-
value SNP P-value 
rs714831 0.0022 rs760233 0.0093 rs714830 0.0135 rs1885512 0.0183 
rs2294809 0.037 rs1158282 0.0206 rs736425 0.0208 rs2273796 0.0086 
rs2328529 0.0011 rs2302592 0.0465 rs1548145 0.0117 rs7078328 0.0165 
rs2328549 0.0001 rs2303345 0.0458 rs2305955 0.0394 rs7098436 0.0098 
rs2328573 0.0183 rs2359866 0.0267 rs2820001 0.0188 rs10510107 0.0165 
rs2819999 0.0246 rs2359983 0.0177 rs6905567 0.0354 rs10788281 0.0167 
rs4236002 0.0054 rs4903350 0.0273 rs6926388 0.0237 rs11200528 0.0132 
rs4291090 0.0163 rs4903359 0.0089 rs6927356 0.0478 rs11200537 0.0351 
rs4413596 0.032 rs6574258 0.0092 rs6938184 0.0183   
rs4527692 0.0254 rs7156551 0.0356 rs7747752 0.0468   
rs6456368 2.0E-05 rs8015242 0.0441 rs7754840 0.0075   
rs6908425 0.0074 rs8020986 0.0396 rs7767391 0.0365   
rs7739578 0.0064 rs9323619 0.0178 rs9460546 0.0057   
rs7739596 0.0076 rs10131117 0.0053 rs9465871 0.0445   
rs7741604 0.0198 rs10143790 0.0353 rs10484632 0.0122   
rs7747752 0.0018 rs11621464 0.0394 rs10946398 0.0059   
rs7752602 0.0351 rs11621718 0.0129 rs11970425 0.0375   
rs7754840 4.5E-05 rs12887886 0.0427 rs16884481 0.0073   
rs7763304 0.0067 Gene 
 P-
value Gene 
 P-
value   
rs7766346 0.0271 BTBD16 5.0E-08 TTLL5 4.0E-07   
rs7767391 5.5E-06 N0 of SNPs 31 N0 of SNPs 21   
rs9348440 8.5E-05 SNP 
P-
value SNP 
P-
value   
rs9350257 0.0427 rs1022782 0.0017 rs760233 0.0316   
rs9358395 0.0071 rs4237539 0.0021 rs4903359 0.0268   
rs9366357 0.0057 rs4317918 0.0027 rs6574258 0.0129   
rs9368283 0.0157 rs7078328 0.004 rs8018962 0.0272   
rs9460546 3.7E-05 rs10510107 0.0025 rs8020986 0.0382   
rs9465871 1.0E-06 rs10887121 0.0053 rs10131117 0.0128   
rs10946398 2.5E-05 rs10887122 0.001 rs11621464 0.0231   
rs16883996 0.0469 rs11200528 0.002 rs17183738 0.0454   
  rs11200537 0.0053     
 
  
Table 3.  The number of pathways showing significant association 
 
 
 
 
 
 
 Number of pathways Sources Disease 
Exact Simes/FDR 
BD 15     3.23% 22    4.73% 
CAD 22     4.73% 28     6.02% 
CD 26     5.59% 77     16.56% 
HT 23     4.95% 21     4.52% 
RA 36     7.74% 67     14.41% 
T1D 24     5.16% 136     29.25% 
WTCCC 
T2D 33     7.10% 28     6.02% 
DGI T2D 53     
11.40% 
24     5.16% 
NARAC & 
EIRA 
RA 40     8.60% 103     22.15% 
CORIELL PD 24     5.16% 47     10.11% 
NCBI PD 15     3.23% 31     6.67% 
CORIELL ALS 35     7.53% 29     6.24% 
NCBI AREDS 26     5.59% 104     22.37% 
  
 
Table 4.  Number of replicated or shared pathways 
Study 1 Study 2 Exact Simes/FDR 
RA (WTCCC) RA(NARAC & 
EIRA) 
7 45 
T2D (WTCCC) T2D (DGI) 5 10 
PD(CORIELL) PD(NCBI) 10 30 
WTCCC 
Number of shared pathways  
Exact Simes/FDR 
CAD+HT+T2D  1 0 
RA+T1D 6 49 
CD+RA+T1D 1 7 
 
 
